Brind.

Arbutus Biopharma operates within the biomedical and genetics sector, and its stock performance was compared to the S&P 500.

2 reports, 1 independent Updated Aug 12
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Arbutus Biopharma operates within the biomedical and genetics sector, and its stock performance was compared to the S&P 500.

Who's involved

What this event is mainly about
Arbutus Biopharma

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • ZacksArbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates Arbutus Biopharma (ABUS) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02
1 more outlet ran the same wire story